HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients.

about

HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients.

Item

http://www.wikidata.org/entity/Q47138788

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

HCV kinetic and modeling analy ...... chronic HCV-infected patients.

@en

HCV kinetic and modeling analy ...... chronic HCV-infected patients.

@nl

type

Item

label

HCV kinetic and modeling analy ...... chronic HCV-infected patients.

@en

HCV kinetic and modeling analy ...... chronic HCV-infected patients.

@nl

prefLabel

HCV kinetic and modeling analy ...... chronic HCV-infected patients.

@en

HCV kinetic and modeling analy ...... chronic HCV-infected patients.

@nl

P1476

HCV kinetic and modeling analy ...... chronic HCV-infected patients.

@en

P2093

Harel Dahari

http://www.w3.org/2001/XMLSchema#string

Kazuaki Chayama

http://www.w3.org/2001/XMLSchema#string

Michio Imamura

http://www.w3.org/2001/XMLSchema#string

Scott J Cotler

http://www.w3.org/2001/XMLSchema#string

Susan L Uprichard

http://www.w3.org/2001/XMLSchema#string

Yoshiiku Kawakami

http://www.w3.org/2001/XMLSchema#string

P2860

Distinction between chronic hepatitis and liver cirrhosis in patients with hepatitis C virus infection. Practical discriminant function using common laboratory data.

Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics.

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.

Modeling quasispecies and drug resistance in hepatitis C patients treated with a protease inhibitor

HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.

Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies

Emerging treatments for chronic hepatitis C.

The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics?

The practical management of chronic hepatitis C infection in Japan - dual therapy of daclatasvir + asunaprevir.

Urgency to treat patients with chronic hepatitis C in Asia.

P304

e0187409

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0187409

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Laetitia Canini

P577

2017-12-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29216198

http://www.w3.org/2001/XMLSchema#string

P932

5720697

http://www.w3.org/2001/XMLSchema#string